Management of Methamphetamine-Positive Patient on Vyvanse and Suboxone
Continue the Suboxone (buprenorphine/naloxone) without interruption, as ongoing methamphetamine use is not a contraindication to opioid use disorder treatment and discontinuation significantly increases overdose risk 1. However, you must immediately reassess the Vyvanse prescription, as this patient is demonstrating active stimulant misuse while receiving a Schedule II amphetamine prodrug with significant abuse potential 2.
Immediate Actions for Vyvanse
Discontinue Vyvanse immediately. The FDA labeling explicitly warns that misuse and abuse of lisdexamfetamine can result in overdose and death, with risks increased at higher doses 2. Prescribing an amphetamine derivative to someone actively using methamphetamine creates multiple dangers:
- Cardiovascular risk: Combined stimulant exposure increases risk of tachyarrhythmias, hypertension, vasospasm, myocardial infarction, and sudden cardiac death 2
- CNS toxicity: Heightened risk of psychosis, aggression, seizures, hyperthermia, and serotonin syndrome 2
- Diversion potential: The patient may be diverting the Vyvanse or using it to potentiate methamphetamine effects
The positive methamphetamine screens indicate either:
- Active methamphetamine use disorder requiring treatment
- Diversion/misuse of the prescribed Vyvanse (which metabolizes to d-amphetamine and can cross-react on some drug screens)
- Both
Suboxone Management Strategy
Maintain or optimize the buprenorphine/naloxone dose while addressing the concurrent stimulant use. The evidence shows:
- Relapse to other substances during buprenorphine treatment is common and not incompatible with eventual successful treatment 1
- Methamphetamine use increases risk of OAT discontinuation (hazard ratio 2.06-2.45), but this effect is less pronounced with buprenorphine than with naltrexone 3
- Neither buprenorphine nor methadone significantly reduces methamphetamine use on their own 4, so don't expect the Suboxone alone to solve the stimulant problem
Critical caveat: The combination of buprenorphine with stimulants increases respiratory depression risk, particularly if benzodiazepines or alcohol are also involved 5. Ensure naloxone is prescribed for overdose prevention 1.
Addressing the Methamphetamine Use
Assessment Requirements
Determine the severity and pattern:
- Days of methamphetamine use in past 28 days
- Route of administration (injection carries highest risk)
- Presence of methamphetamine use disorder criteria
- Cardiac symptoms (chest pain, palpitations, syncope)
- Psychiatric symptoms (psychosis, paranoia, aggression)
- HIV/Hepatitis C risk behaviors
Treatment Options for Methamphetamine Use Disorder
Contingency management is the most effective intervention and should be implemented if available 6, 7. This involves:
- Providing tangible rewards for negative urine drug screens
- Escalating incentives for consecutive negative tests
- Immediate reinforcement of abstinence
Psychosocial interventions are recommended but have modest effect sizes 7:
- Cognitive behavioral therapy
- Matrix Model (if available)
- Self-help and family support groups
Pharmacologic Considerations for Methamphetamine Use Disorder
The 2024 ASAM/AAAP guideline includes a conditional recommendation for long-acting methylphenidate for amphetamine-type stimulant use disorder, but this is based on low-certainty evidence 8.
Lisdexamfetamine (Vyvanse) at 250mg daily showed some benefit in reducing methamphetamine use over 12 weeks in a 2024 RCT, but evidence of sustained benefit at endpoint was weak 6. However, this patient has already demonstrated inability to use prescribed stimulants safely, making them a poor candidate for stimulant agonist therapy.
Do not restart Vyvanse or prescribe methylphenidate unless:
- The patient achieves sustained abstinence from methamphetamine (minimum 4 weeks)
- Demonstrates consistent treatment engagement across 5 domains: adherence, abstinence progress, attendance, alternative activities, and accessing support 8
- Has no cardiac contraindications
- Agrees to frequent monitoring (weekly urine screens initially)
Monitoring Protocol
While continuing Suboxone:
- Weekly urine drug screens for first month, then biweekly
- Assess for hepatotoxicity: Baseline and periodic liver function tests, as both buprenorphine and methamphetamine can cause hepatic injury 5
- Cardiovascular monitoring: Blood pressure and pulse at each visit given stimulant exposure 2
- Psychiatric assessment: Screen for stimulant-induced psychosis, depression, suicidality
- Overdose risk counseling: Emphasize that methamphetamine use increases overdose risk, particularly if opioids are also used
Common Pitfalls to Avoid
- Don't discontinue Suboxone due to methamphetamine use - this dramatically increases opioid overdose risk 1
- Don't assume positive amphetamine screens are from Vyvanse alone - verify with quantitative levels and clinical correlation
- Don't restart stimulant medications without documented behavioral stability - this enables continued misuse 8
- Don't neglect hepatitis screening - injection methamphetamine use carries high HCV transmission risk 5
Treatment should continue for as long as the patient benefits and aligns with their goals 1, but the Vyvanse prescription represents an immediate safety concern requiring discontinuation.